Skip to main content
OpenTrials

Clinical trial condition

Recurrent Oropharyngeal Squamous Cell Carcinoma

Explore clinical trials studying Recurrent Oropharyngeal Squamous Cell Carcinoma. Study availability and eligibility vary by location and protocol.

20 public trials 8 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Oropharyngeal Squamous Cell Carcinoma trial results

Recruiting

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

NCT04671667

Conditions
Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +10 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Kaiser Permanente-Anaheim Anaheim, California, United States
  • Kaiser Permanente-Bellflower Bellflower, California, United States
View all 178 locations
View Trial Details
Recruiting

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

NCT06589804

Conditions
Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +38 more
Locations
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Fremont - Rideout Cancer Center Marysville, California, United States
  • VA Palo Alto Health Care System Palo Alto, California, United States
  • UCHealth Memorial Hospital Central Colorado Springs, Colorado, United States
View all 192 locations
View Trial Details
Recruiting

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

NCT06980038

Conditions
Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +41 more
Locations
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Emory University Hospital Midtown Atlanta, Georgia, United States
  • Ochsner Medical Center Jefferson New Orleans, Louisiana, United States
View Trial Details
Recruiting

Oropharynx (OPX) Biomarker Trial

NCT06356272

Conditions
Carcinoma, Carcinoma, Squamous Cell, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, +29 more
Locations
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
View Trial Details
Completed

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

NCT03422536

Conditions
Carcinoma, Carcinoma, Squamous Cell, HNSCC, +41 more
Locations
  • The University of Arizona Cancer Center Tucson, Arizona, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Winship Cancer Institute of Emory University Atlanta, Georgia, United States
View Trial Details
Completed

Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

NCT01064479

Conditions
Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +29 more
Locations
  • M D Anderson Cancer Center Houston, Texas, United States
  • MD Anderson Regional Care Center-Katy Houston, Texas, United States
  • MD Anderson Regional Care Center-Bay Area Nassau Bay, Texas, United States
  • MD Anderson Regional Care Center-Sugar Land Sugar Land, Texas, United States
View Trial Details

Related conditions